Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01462344 · ClinicalTrials.gov registry record · Phase 4
6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 6,250
- Enrollment target
NCT01462344 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 6,250 participants.
The verdict
NCT01462344, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6,250 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.
Interventions
- DRUG ADVAIR 100/50mcg
- DRUG ADVAIR 250/50mcg
- DRUG FLOVENT 100mcg
- DRUG FLOVENT 250mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,250 participants |
| Start Date | 2011-11-17 |
| Est. Completion | 2015-11-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01462344
The ClinicalTrials.gov registry entry for NCT01462344 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ADVAIR 100/50mcg is the first listed.
NCT01462344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01462344 about?
NCT01462344 is a clinical study titled "6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old". The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone pro...
What is the current status of trial NCT01462344?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6,250 participants. The study started on 2011-11-17. Estimated completion is 2015-11-03.
What interventions are being tested in trial NCT01462344?
The interventions under investigation include: ADVAIR 100/50mcg (DRUG), ADVAIR 250/50mcg (DRUG), FLOVENT 100mcg (DRUG), FLOVENT 250mcg (DRUG).
Who is sponsoring clinical trial NCT01462344?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.